SCHEMBL19320883

SCHEMBL19320883

COCc1ccccc1-c1sc2c(c1C(=O)O)Cc1ccccc1-2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSR P00390 1/20 0.38
KDM4E B2RXH2 8/20 0.37
ALDH1A1 P00352 8/20 0.37
HPGD P15428 7/20 0.37
L3MBTL1 Q9Y468 4/20 0.37
MAPT P10636 4/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
ESR1 P03372 1/20 0.37
LMNA P02545 2/20 0.36
NOTUM Q6P988 1/20 0.36
TDP1 Q9NUW8 3/20 0.34
NPC1 O15118 3/20 0.34
RAB9A P51151 3/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
FFAR1 O14842 2/20 0.34
FFAR4 Q5NUL3 1/20 0.34
CYP11B2 P19099 1/20 0.33
PNMT P11086 1/20 0.33
LIMK1 P53667 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19325610 0.88 GSR (0.38) GSRKDM4EALDH1A1HPGDL3MBTL1
SCHEMBL19320876 0.81 MAPT (0.44) ALDH1A1HPGDL3MBTL1MAPTSMN1; SMN2
SCHEMBL19320877 0.80 MEN1 (0.46) ALDH1A1HPGDL3MBTL1MAPTSMN1; SMN2
SCHEMBL19320878 0.80 MEN1 (0.46) ALDH1A1HPGDL3MBTL1MAPTSMN1; SMN2
SCHEMBL19320879 0.78 ESR1 (0.35) ALDH1A1HPGDMAPTSMN1; SMN2ESR1
SCHEMBL19321474 0.78 PTPN1 (0.41) KDM4EALDH1A1HPGDL3MBTL1MAPT
SCHEMBL19320881 0.77 CACNA1G (0.39) KDM4EALDH1A1HPGDL3MBTL1MAPT
SCHEMBL19320889 0.75 L3MBTL1 (0.51) L3MBTL1ESR1LMNATDP1NPC1
SCHEMBL19320826 0.74 CACNA1G (0.47) KDM4EALDH1A1HPGDMAPTSMN1; SMN2
SCHEMBL19320875 0.74 CACNA1G (0.47) KDM4EALDH1A1HPGDSMN1; SMN2ESR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170253607-A1 LONG-ACTING HIV PROTEASE INHIBITOR SHIONOGI & CO., LTD. (JP) 2017-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170253607-A1 LONG-ACTING HIV PROTEASE INHIBITOR CPN1, HAT1, PRSS1 GSR 3048/4885KDM4E 1195/4885ALDH1A1 4195/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.